Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CStone closes $260mm Series B round; largest in Chinese biopharm history

Executive Summary

Immuno-oncology firm CStone Pharmaceuticals Co. Ltd. raised $260mm through its Series B round, the largest funding of its kind in Chinese biopharma history. GIC Private Ltd. led and was joined by new investors Sequoia China, Yunfeng Capital, 6 Dimensions Capital, CITIC PE, Taikang Insurance Group, Arch Venture Partners, Hillhouse Capital, King Star Capital, 3W Partners, AVICT, and Terra Mafnum Capital Partners, as well as returning backers Oriza Seed Venture Capital, Boyu Capital, and WuXi Healthcare Ventures. Funds will support continued development of lead candidate CS1001, an anti-PD-L1 mAb in Phase I/II for advanced cancers.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies